LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Innovative Technology Identifies Broad Range of Pathogens

By LabMedica International staff writers
Posted on 23 Sep 2014
Abbott\'s diagnostic platform system IRIDICA for the identification of pathogens
The diagnostic platform system IRIDICA for the identification of pathogens (Photo courtesy of ABBOTT Corporate)
A platform has been developed with the goal to deliver a broad range of tests that can identify hundreds of bacteria, fungi, and viruses directly from a patient specimen within eight hours.

The pioneering testing technology could reduce hospital stays by up to eight days and lower annual health care costs for people with serious infections by approximately USD 2.2 million.

The cost reductions were based on a health economic model from the RApid Diagnosis of Infections in the CriticAlly IlL (RADICAL) study. An independent, expert panel of physicians reviewed the RADICAL study results from samples obtained from 420 critically ill patients with suspected severe infections from the United Kingdom, France, Belgium, Poland, Switzerland, and Germany.

The RADICAL study indicated that polymerase chain reaction/Electrospray Ionization Mass Spectrometry or PCR/ESI-MS (Abbott, Abbot Park, IL, USA) has the ability to detect the source of the infection such as bacteria, fungi, or viruses, within hours, even when blood cultures, the current standard of care, are negative. This information could help doctors diagnose and initiate appropriate treatments more quickly.

The platform known as IRIDICA currently differentiates between 600 bacterial families, as well as 200 families of fungi and 13 families of viruses. The PCR/ESI-MS technology may offer the potential for earlier discontinuation of broad-spectrum antibiotics. After retrospectively comparing Abbott's technology versus culture, the physicians reported they would have prescribed a different course of treatment in 57% of the cases evaluated based on the Abbott technology results.

Jean-Louis Vincent, MD, PhD, professor of Intensive Care at the Universite Libre de Bruxelles (Brussels, Belgium) said, “More than 50% of blood culture tests come back negative, even when infections are believed to exist. The results of the RADICAL study and the economic analysis suggest the Abbott technology will provide actionable information much earlier, allow physicians to improve patient outcomes and may ultimately lower overall health care costs related to these serious infections.” The IRIDICA platform is expected to be available as a Conformité Européenne (CE) marked in vitro diagnostic device in European countries within the coming months. The study was presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy held September 5-9, 2014, in Washington DC (USA).

Related Links:

Abbott
Universite Libre de Bruxelles


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more